Cargando…
Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer
Microtubule targeting agents (MTAs) such as taxanes are broadly used for the treatment of patients with cancer. Although MTAs are not effective for treatment of colorectal cancer (CRC), preclinical studies suggest that a subset of patients with CRC, especially those with cancers harboring the BRAF m...
Autores principales: | Yoshihiro, Tomoyasu, Ariyama, Hiroshi, Yamaguchi, Kyoko, Imajima, Takashi, Yamaga, Satoru, Tsuchihashi, Kenji, Isobe, Taichi, Kusaba, Hitoshi, Akashi, Koichi, Baba, Eishi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746063/ https://www.ncbi.nlm.nih.gov/pubmed/36053154 http://dx.doi.org/10.1111/cas.15558 |
Ejemplares similares
-
Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020) -
Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report
por: Yamaguchi, Kyoko, et al.
Publicado: (2021) -
Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer
por: Taguchi, Ryosuke, et al.
Publicado: (2020) -
Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017) -
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Shimada, Eijiro, et al.
Publicado: (2021)